Want to see IN:IKS full AI Analyst Report?
Top Page
Inventurus Knowledge Solutions Limited
(IKS)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹1,999.00
▲(13.54% Upside)
Action:Reiterated
Date:07/02/26
The score is driven primarily by strong financial performance (high margins and robust earnings growth) and supportive technical momentum (price above key moving averages with positive MACD). The main offset is valuation: the high P/E suggests much of the growth may already be priced in, and recent operating cash flow coverage weakness adds an additional quality/volatility watchpoint.
Positive Factors
High profitability
Sustained high operating and net margins indicate structural cost advantages or high-value service mix in healthcare RCM. Durable margins support reinvestment, strong ROE and cash generation capacity, enabling the company to fund growth, tech investment, or buffer economic downturns.
Negative Factors
Margin volatility
Past swings and inconsistent gross/profit metrics reduce confidence in sustaining elevated margins. For a services provider, margin variability can stem from client mix shifts, pricing resets, or temporary cost absorption, making long-term margin predictability and planning harder.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability
Sustained high operating and net margins indicate structural cost advantages or high-value service mix in healthcare RCM. Durable margins support reinvestment, strong ROE and cash generation capacity, enabling the company to fund growth, tech investment, or buffer economic downturns.
Read all positive factors
Inventurus Knowledge Solutions Limited (IKS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹290.84B
Dividend YieldN/A
Average Volume (3M)29.94K
Price to Earnings (P/E)38.0
Beta (1Y)0.87
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees9,698
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)31.90
Shares Outstanding171,573,170
10 Day Avg. Volume15,907
30 Day Avg. Volume29,940
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)7.94
Price to Sales (P/S)6.96
P/FCF Ratio37.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,900.00Price Target Upside7.92% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)54.04
Revenue Forecast (FY)₹46.68B
Inventurus Knowledge Solutions Limited Business Overview & Revenue Model
Company Description
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States...
How the Company Makes Money
IKS primarily makes money by providing outsourced, contract-based services to healthcare clients and billing for those services under commercial arrangements such as recurring service fees (e.g., monthly/term-based fees) and/or transaction/volume-...
Inventurus Knowledge Solutions Limited Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
72
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.63B | 31.94B | 26.64B | 18.17B | 10.31B | 7.64B |
| Gross Profit | 8.37B | 14.41B | 26.63B | 18.16B | 5.05B | 3.59B |
| EBITDA | 8.47B | 11.54B | 8.09B | 5.61B | 3.89B | 2.98B |
| Net Income | 5.33B | 7.22B | 4.86B | 3.70B | 3.05B | 2.33B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 42.68B | 30.52B | 30.28B | 9.88B | 7.88B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92B | 6.09B | 2.19B | 4.83B | 5.23B | 3.47B |
| Total Debt | 0.00 | 7.53B | 8.56B | 13.11B | 523.46M | 651.92M |
| Total Liabilities | -17.90B | 14.68B | 12.62B | 18.70B | 1.60B | 1.40B |
| Stockholders Equity | 17.90B | 28.00B | 17.90B | 11.58B | 8.29B | 6.47B |
Cash Flow | ||||||
| Free Cash Flow | 1.06B | 6.00B | 2.93B | 1.77B | 2.79B | 2.22B |
| Operating Cash Flow | 1.19B | 6.32B | 3.18B | 2.10B | 2.88B | 2.33B |
| Investing Cash Flow | 1.42B | -2.15B | 2.44B | -11.41B | -1.56B | -824.48M |
| Financing Cash Flow | -1.37B | -3.65B | -3.89B | 7.80B | -1.52B | -585.10M |
Inventurus Knowledge Solutions Limited Technical Analysis
Negative
1760.60
Price Trends
1810.15
Negative
1731.72
Positive
1646.57
Positive
Market Momentum
-8.80
Negative
42.81
Neutral
41.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IKS, the sentiment is Negative. The current price of 1760.6 is below the 20-day moving average (MA) of 1775.34, below the 50-day MA of 1810.15, and above the 200-day MA of 1646.57, indicating a neutral trend. The MACD of -8.80 indicates Negative momentum. The RSI at 42.81 is Neutral, neither overbought nor oversold. The STOCH value of 41.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:IKS.
Inventurus Knowledge Solutions Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹28.13B | 35.33 | ― | 0.32% | 14.22% | 7.17% | |
74 Outperform | ₹139.29B | 34.75 | ― | 0.39% | 30.41% | -8.20% | |
72 Outperform | ₹290.84B | 38.04 | ― | ― | ― | ― | |
65 Neutral | ₹336.56B | 92.31 | ― | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹154.46B | 69.65 | ― | 0.33% | -3.41% | -56.45% | |
41 Neutral | ₹163.28B | 46.09 | ― | 0.49% | 16.27% | -23.50% |
* General Sector Average
IN:IKS
Inventurus Knowledge Solutions Limited
1,736.25
164.55
10.47%
IN:INDGN
Indegene Limited
578.05
6.91
1.21%
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,025.10
-90.23
-8.09%
IN:SYNGENE
Syngene International Ltd.
382.65
-286.26
-42.79%
IN:VIMTALABS
Vimta Labs Limited
629.50
-161.43
-20.41%
IN:SAILIFE
SAI Life Sciences Ltd.
1,585.20
704.15
79.92%
Inventurus Knowledge Solutions Limited Corporate Events
Inventurus Knowledge Solutions backs TruBridge acquisition with USD 603.75 million guarantee and refinancing
Jul 6, 2026
Inventurus Knowledge Solutions Limited has issued a corporate guarantee of up to USD 603.75 million in favour of a consortium of global and Indian lenders, backing facilities of up to USD 575 million to be availed by its wholly owned U.S. subsidia...
Inventurus Knowledge Solutions Secures Financing Framework for TruBridge Acquisition
Jul 3, 2026
Inventurus Knowledge Solutions Limited has detailed the execution of key financing and security agreements tied to its planned acquisition of TruBridge, Inc. by its wholly owned U.S. subsidiary, Inventurus Knowledge Solutions, Inc. The company, al...
Inventurus Knowledge Solutions Tightens Security Package, Trims Loan Size for TruBridge Deal
Jul 2, 2026
Inventurus Knowledge Solutions Limited has revised the financing structure for its pending acquisition of U.S.-based TruBridge, Inc. by reducing the proposed borrowing by its wholly owned subsidiary IKS Inc. from up to USD 670 million to up to USD...
Inventurus Knowledge Solutions Secures CARE A+ Stable Issuer Rating
Jun 19, 2026
Inventurus Knowledge Solutions Limited announced that CARE Ratings Limited has assigned the company an issuer rating of CARE A+ with a Stable outlook. The rating reflects CARE’s opinion on the general creditworthiness of the company, potenti...
Inventurus Knowledge Solutions Sets Q4 FY 2025-26 Earnings Call for May 14
May 9, 2026
Inventurus Knowledge Solutions Limited has announced the schedule for its earnings conference call to discuss financial results for the fourth quarter of fiscal year 2025-26, to be held on Thursday, May 14, 2026, at 8:30 a.m. India Standard Time. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.